MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Kisspeptin in the Evaluation of Delayed Puberty

Phase 1

Completed

Conditions: Delayed Puberty
Hypogonadotropic Hypogonadism
Kallmann Syndrome
GnRH Deficiency

Interventions: Drug: kisspeptin 112-121
Drug: GnRH

First Posted Date: 2011-09-21

Last Posted Date: 2023-10-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 24

Registration Number: NCT01438034

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Non-Invasive Imaging for Cording in Breast Cancer Patients

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: Non invasive venous ultrasound

First Posted Date: 2011-09-01

Last Posted Date: 2016-03-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 5

Registration Number: NCT01427166

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Growth Hormone Treatment on Phosphocreatine Recovery in Obesity

Not Applicable

Completed

Conditions: Growth Hormone Secretion Abnormality
Obese

Interventions: Drug: Growth hormone treatment

First Posted Date: 2011-08-23

Last Posted Date: 2014-07-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 15

Registration Number: NCT01421589

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Creatine Safety & Tolerability in Huntington's Disease

Phase 2

Completed

Conditions: Huntington's Disease (HD)

Interventions: Drug: Creatine monohydrate

First Posted Date: 2011-08-09

Last Posted Date: 2018-03-09

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 10

Registration Number: NCT01412151

Locations: 🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States

Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability

Phase 2

Completed

Conditions: Huntington's Disease

Interventions: Drug: Creatine monohydrate

First Posted Date: 2011-08-08

Last Posted Date: 2014-02-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 24

Registration Number: NCT01411163

Locations: 🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States

Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study

Phase 2

Completed

Conditions: Huntington's Disease

Interventions: Drug: Creatine Monohydrate

First Posted Date: 2011-08-08

Last Posted Date: 2014-02-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 38

Registration Number: NCT01411150

Locations: 🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States

Reduced Intensity Double Umbilical Cord Blood Transplantation

Phase 2

Completed

Conditions: Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Multiple Myeloma
Acute Myelogenous Leukemia

Interventions: Drug: Fludarabine
Drug: Melphalan
Radiation: Total Body Radiation
Biological: Cord Blood

First Posted Date: 2011-08-03

Last Posted Date: 2019-01-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 33

Registration Number: NCT01408563

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV

Completed

Conditions: HIV-infection

Interventions: Drug: Angiotensin II Infusion

First Posted Date: 2011-08-02

Last Posted Date: 2016-08-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT01407237

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Nilotinib With Radiation for High Risk Chordoma

Phase 1

Active, not recruiting

Conditions: Chordoma

Interventions: Drug: Nilotinib
Radiation: Radiation therapy

First Posted Date: 2011-08-02

Last Posted Date: 2024-03-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 29

Registration Number: NCT01407198

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

IGF-1 and Bone Loss in Women With Anorexia Nervosa

Not Applicable

Completed

Conditions: Osteopenia
Anorexia Nervosa
Osteoporosis

Interventions: Drug: Placebo
Drug: rhIGF-1
Drug: Risedronate

First Posted Date: 2011-08-01

Last Posted Date: 2020-07-17

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 148

Registration Number: NCT01406444

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy